Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

European Journal of Cancer

Volumn 41, Issue 12, 2005, Pages 1739-1745

  Delbaldo, Catherine ^a   Pierga, Jean Yves ^b   Dieras, Véronique ^b   Faivre, Sandrine ^a   Laurence, Valérie ^b   Vedovato, Jean Claude ^c   Bonnay, Marc ^a   Mueser, Matthias ^c   Nolting, Arno ^c   Kovar, Andreas ^c   Raymond, Eric ^a,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT CURIE   (France)

^c MERCK KGAA   (Germany)

^d BEAUJON HOSPITAL   (France)

Author keywords

C225; Colon cancer; EGFR inhibitor; Phase I

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COMPARTMENT MODEL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRY SKIN; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; RASH; SKIN TOXICITY;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 23644457632     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.04.029     Document Type: Article

References (29)

1. J. Schlessinger The epidermal growth factor receptor as a multifunctional allosteric protein Biochemistry 27 1988 3119 3123
2. E. Raymond, S. Faivre, and J.P. Armand Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy Drugs 60 Suppl. 1 2000 15 23
3. J. Price, H.M. Wilson, and N.E. Haites Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704 Eur J Cancer A 32 1996 1977 1982
4. H. Xie, T. Turner, and M.H. Wang In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals Clin Exp Metastas 13 1995 407 419
5. G. Todderud, and G. Carpenter Epidermal growth factor: the receptor and its function Biofactors 2 1989 11 15
6. R.I. Nicholson, J.M. Gee, and M.E. Harper EGFR and cancer prognosis Eur J Cancer 37 Suppl. 4 2001 S9 S15
7. O. Dassonville, J.L. Formento, and M. Francoual Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer J Clin Oncol 11 1993 1873 1878
8. J. Mendelsohn, and J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 2000 6550 6565
9. E.S. Kim, F.R. Khuri, and R.S. Herbst Epidermal growth factor receptor biology (IMC-C225) Curr Opin Oncol 13 2001 506 513
10. J. Mendelsohn Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy Clin Cancer Res 3 1997 2703 2707
11. R. Perez-Soler, N.J. Donato, and D.M. Shin Tumour epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852 J Clin Oncol 12 1994 730 739
12. B. Liu, M. Fang, and M. Schmidt Induction of apoptosis and activation of the caspase cascade by anti- EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity Br J Cancer 82 2000 1991 1999
13. J. Albanell, J. Codony-Servat, and F. Rojo Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments Cancer Res 61 2001 6500 6510
14. J. Baselga, D. Pfister, and M.R. Cooper Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin J Clin Oncol 18 2000 904 914
15. D.M. Shin, N.J. Donato, and R. Perez-Soler Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer Clin Cancer Res 7 2001 1204 1213
16. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer New Engl J Med 351 2004 337 345
17. P. Rougier, E. Van Cutsem, and E. Bajetta Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 1998 1407 1412
18. J.Y. Douillard, D. Cunningham, and A.D. Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047
19. J.G. Slatter, P. Su, and J.P. Sams Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions Drug Metab Dispos 25 1997 1157 1164
20. L. Iyer, D. Hall, and S. Das Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism Clin Pharmacol Ther 65 1999 576 582
21. F. Ciardiello, R. Bianco, and V. Damiano Antitumour activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 Clin Cancer Res 5 1999 909 916
22. M.C. Prewett, A.T. Hooper, and R. Bassi Enhanced antitumour activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumour xenograft Clin Cancer Res 8 5 2002 993 1003
23. L.B. Saltz, M. Rubin, and H. Hochster Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) Proc Am Soc Clin Oncol 20 2001 7
24. I. Barilero, D. Gandia, and J.P. Armand Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients J Chromatogr 575 1992 275 280
25. L.P. Rivory, and J. Robert Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan Cancer Chemother Pharmacol 36 1995 176 179
26. A. Santos, S. Zanetta, and T. Cresteil Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans Clin Cancer Res 6 2000 2012 2020
27. L.P. Rivory, M.C. Haaz, and P. Canal Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials Clin Cancer Res 3 1997 1261 1266
28. L. Saltz, N.J. Meropol, and P.J. Loehrer Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208
29. P. Rougier, R. Bugat, and J.Y. Douillard Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy J Clin Oncol 15 1997 251 260